Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Gastrointestinal 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Liposarcoma 1

Interventions

Temozolomide 102Radiotherapy 47Bevacizumab 33Carboplatin 23Irinotecan 20pembrolizumab 17Radiosurgery 16Nivolumab 16Radiation 14Cyclophosphamide 11Magnetic Resonance Spectroscopy 10fludarabine 8Trastuzumab 8Radiotherapy, Intensity-Modulated 8Carmustine 8Surgical Procedures, Operative 7Specimen Handling 7Pemetrexed 7Paclitaxel 7Interleukin-2 7Filgrastim 7Everolimus 7Erlotinib Hydrochloride 7temsirolimus 6Vorinostat 6Radiotherapy, Conformal 6Lomustine 6Ipilimumab 6Granulocyte-Macrophage Colony-Stimulating Factor 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × silmitasertib × CNS × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT03904862 2025-10-30

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Pediatric Brain Tumor Consortium

Phase 1/2 Terminated
21 enrolled
CNS

Microphthalmia, Isolated, with Coloboma 5, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡